K-ASSAY CRP (Ver.2)
C-Reactive Protein, Antigen, Antiserum, And Control. 510(k) K242170, from Kamiya Biomedical Company, LLC (Tukwila, WA). Product code DCK, class 2.
As of Nov 17, 2026, K242170 is an FDA 510(k) held by Kamiya Biomedical Company, LLC, substantially equivalent on Apr 18, 2025 after 268 days, with no recalls tied to it in FDA's recall database.
- Substantially equivalent: Apr 18, 2025
- Review time: 268 days
- Recalls: 0
Indications for Use
As the 510(k) summary states them, read from FDA's summary PDFK-ASSAY CRP (Ver.2) is intended to be used for the quantitative determination of C-reactive protein (CRP) in human serum and plasma (potassium-EDTA or lithium-heparin) by immunoturbidimetric assay. Measurement of CRP aids in the detection and evaluation of infection, tissue injury, inflammatory disorders and associated diseases. FOR IN VITRO DIAGNOSTIC USE.
Predicate Devices
The legally marketed devices this 510(k) summary says it is substantially equivalent to, read from FDA's summary PDF- K-Assay C-Reactive Protein (3), K-Assay Crp Multi-Calibrator D, K-Assay Crp…K023828 · Kamiya Biomedical Co. · Feb 4, 2003
Other DCK Clearances
The newest 510(k)s for the same product code; see every DCK device- Procise CRP, ProciseDx Analyzer, ProciseDx Calibration CartridgeK201256 · Procise Diagnostics · Nov 4, 2022
Record
- Document
- 510(k) summary (PDF) ↗
- Type
- Traditional
- Received
- Jul 24, 2024
- Review panel
- Immunology
- Regulation
- 21 CFR 866.5270
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files